Skip to main content
2026 Prospectus
Prenatal-onset GBS Disease Recognition Month 2026 executive healthcare observance hero.

· Executive Brief

Prenatal-onset GBS Disease Recognition Month 2026

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 33 min read

Leadership signal

Recognition becomes useful when leaders inspect the real route.

The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

GBS prevention depends on steps that happen weeks apart

Group B streptococcal disease is often described as a single clinical event at birth. For health systems it is a chain of dependencies that begins in prenatal care, passes through the laboratory and the labor unit, and continues through the first three months of life. In multistate population-based surveillance of U.S. infants younger than 90 days, early-onset disease incidence declined from 0.37 to 0.23 per 1000 live births between 2006 and 2015.[15] Late-onset disease remained stable at a mean of 0.31 per 1000 live births.[15] An estimated 840 early-onset and 1265 late-onset cases occurred nationally in 2015, and the authors concluded that late-onset rates among U.S. infants are now higher than early-onset rates.[15]

The prenatal part of the story is easy to overlook. In postmortem investigation of deaths in seven low- and middle-income countries, group B streptococcus was in the causal pathway for 2.3% (31 of 1322) of stillbirths.[10] The authors described a substantial, previously underestimated effect on stillbirth in those settings.[10] That finding comes from a different health context than most U.S. systems, but it reinforces why this observance focuses attention on care before labor begins.

The operating risk for executives sits in the gaps between steps. Among the mothers of 1277 U.S. infants with early-onset disease, 278 (21.8%) did not receive intrapartum prophylaxis despite having an indication for it, and 617 (48.3%) had no indication and did not receive it.[15] The first figure describes delivery failures that organizations can manage. The second describes the limits of current screening and risk detection, which matters for how leaders set expectations.

The sections below summarize current peer-reviewed evidence on screening timing, prophylaxis delivery, penicillin allergy labels, laboratory methods, newborn follow-through, late-onset disease, equity and communication. They sit beside the executive guidance already on this page and give boards and operating leaders a shared factual base for choosing one handoff to improve first.

Current evidence

What the research says about screening timing, prophylaxis and allergy labels

Screening timing has already been redesigned once. In 2019, the American College of Obstetricians and Gynecologists recommended moving universal prenatal group B streptococcus screening from 35 0/7 to 37 6/7 weeks of gestation to 36 0/7 to 37 6/7 weeks.[3] The aim was results that remain accurate up to 41 0/7 weeks.[3] In U.S. surveillance data, there were 2,640 early-onset cases (0.24 per 1,000 live births) in 2016 to 2018 and 2,120 cases (0.20 per 1,000 live births) in 2020 to 2022.[3] The annual percent change was 2.1% before the change and −9.6% after it.[3] The authors judged the decline reassuring and supportive of current practice.[3] For operations, a narrower window means the 36- to 37-week visit, specimen and result have less room for delay.

A positive screen does not guarantee adequate prophylaxis. A retrospective cohort included 1,609 GBS-positive women with term singleton pregnancies eligible for vaginal birth.[8] Among women without membrane stripping, 46.9% (694 of 1,480) reached adequate prophylaxis, defined as at least 4 hours of beta-lactam antibiotics before delivery.[8] After excluding women who arrived in active labor and delivered in under 4 hours, adequacy in that group was 85.8%.[8] Much of the gap therefore reflects arrival timing and labor speed, which places triage, order entry and first-dose administration at the center of performance.

Penicillin allergy labels change which antibiotic is given. Among 11,334 GBS-positive mother-infant pairs at a high-volume urban hospital between 2005 and 2018, 1170 (10.3%) mothers had a documented penicillin allergy.[11] Of these, 49 (4.2%) received a penicillin, 259 (22.1%) cefazolin, 449 (38.4%) clindamycin and 413 (35.3%) vancomycin.[11] Alternative prophylaxis was used for 73.7% of patients with an allergy label compared with 0.2% of those without one.[11] In a separate large health system, 940 of 10,969 pregnant women (8.6%) carried a penicillin allergy label.[6]

Laboratory findings shape both choices. In the national surveillance study, no beta-lactam resistance was identified, while 359 isolates tested (20.8%) showed constitutive clindamycin resistance.[15] That combination makes accurate allergy evaluation and reliable susceptibility information more than a pharmacy detail: it affects whether a patient with an allergy label receives an agent to which the organism is susceptible.

Taken together, the evidence shows a prevention model that works when each step is completed on time. It loses reliability at predictable points: the timing of the screening visit, arrival in labor, allergy labels and laboratory information. Each of those points has an operational owner.

Figure 1

Prophylaxis reaches fewer patients when labor is fast or a penicillin label goes unevaluated

Prophylaxis reaches fewer patients when labor is fast or a penicillin label goes unevaluatedPercent of patients receiving adequate intrapartum GBS prophylaxis (at least 4 hours of beta-lactam before delivery) or receiving a penicillin for prophylaxis, as defined in each study. Values are copied from the cited studies [4], [8], [11]; none is estimated.0%25%50%75%100%Adequate prophylaxis, GBS-positive womenwithout membrane strippingAdequate prophylaxis, GBS-positive women without membrane stripping: 46.9% (source [8])46.9%[8]Adequate prophylaxis, same group afterexcluding arrival in active labor withAdequate prophylaxis, same group after excluding arrival in active labor with birth in under 4 hours: 85.8% (source [8])85.8%[8]Penicillin G for GBS prophylaxis,labeled patients not seen in allergyPenicillin G for GBS prophylaxis, labeled patients not seen in allergy clinic: 24.5% (source [4])24.5%[4]Penicillin G for GBS prophylaxis,patients de-labeled in allergy clinicPenicillin G for GBS prophylaxis, patients de-labeled in allergy clinic: 87.5% (source [4])87.5%[4]Received a penicillin, GBS-positivemothers with a documented penicillinReceived a penicillin, GBS-positive mothers with a documented penicillin allergy: 4.2% (source [11])4.2%[11]Source [8]Source [4]Source [11]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of patients receiving adequate intrapartum GBS prophylaxis (at least 4 hours of beta-lactam before delivery) or receiving a penicillin for prophylaxis, as defined in each study. Values are copied from the cited studies [4], [8], [11]; none is estimated.

Data note. Each pair of bars from the same study can be read together, but values from different studies, settings, years and definitions are an indirect comparison and should not be ranked against one another.

Limitation. All three studies are single-institution and retrospective; adequacy is defined by antibiotic timing, and receipt of a penicillin is not the same measure as adequacy.

Figure data (5 rows)
Figure 1 data: Prophylaxis reaches fewer patients when labor is fast or a penicillin label goes unevaluated
MeasureValuePopulation, setting and year as reportedSource
Adequate prophylaxis, GBS-positive women without membrane stripping46.9%694 of 1,480 women with term singleton pregnancies eligible for vaginal birth; retrospective cohort[8]
Adequate prophylaxis, same group after excluding arrival in active labor with birth in under 4 hours85.8%Sensitivity analysis in the same retrospective cohort[8]
Penicillin G for GBS prophylaxis, labeled patients not seen in allergy clinic24.5%Obstetric patients with a penicillin allergy label, academic health system, June 2021 to July 2023[4]
Penicillin G for GBS prophylaxis, patients de-labeled in allergy clinic87.5%Same cohort; patients whose label was removed after evaluation[4]
Received a penicillin, GBS-positive mothers with a documented penicillin allergy4.2%49 of 1170 mothers, high-volume urban hospital, 2005 to 2018[11]
A midwife explains late-pregnancy screening to an expectant couple, the woman visibly pregnant in a soft sweater beside her partner, all seated and seen from the side….
Illustrative image. Laboratory methods affect how reliably GBS colonization is detected before birth.[5]

Continuum of care

Where the pathway breaks between the screening visit, birth and the first 90 days

The GBS pathway crosses more boundaries than most perinatal processes. A specimen is collected in a clinic, processed in a laboratory and reported into a prenatal record. It is then carried to a labor unit that may be in a different facility, and acted on by a team that did not order the test. The newborn’s care then depends on what was documented about maternal status and prophylaxis. Each transfer is a point where a result can be present in one system and absent in another.

Labor arrival is the moment when the pathway is most time-sensitive. In the cohort described above, women who had membrane stripping reached adequate prophylaxis more often than those who did not (64.3% versus 46.9%), and the authors reported that stripping did not impede adequate prophylaxis.[8] Whatever the clinical choice, late-pregnancy outpatient contacts are moments when the organization can confirm that GBS status and allergy information are visible to the labor team before admission.

Maternal decisions carry into newborn care. Neonates of mothers who received alternative prophylaxis had more postnatal laboratory draws than neonates of mothers given beta-lactam antibiotics (20.8% versus 17.3%; adjusted odds ratio 1.23).[11] Newborn evaluation for possible early-onset sepsis is itself a large workload. At a Canadian tertiary center between 2013 and 2023, 1,824 of 34,668 late-preterm and term newborns (5.3%) received intravenous antibiotics in the first week for suspected early-onset sepsis.[1] Culture-proven early-onset sepsis occurred in 0.55 per 1,000 livebirths.[1] For each confirmed case, 96 newborns received antibiotics.[1] The authors suggested that standardized benchmarking indicators could help guide stewardship.[1]

The continuum does not end at discharge. Late-onset disease begins between 7 and 89 days of life, its U.S. rate remained stable through 2015, and the surveillance authors noted that there is no current public health intervention for it.[15] In the multicountry postmortem study, group B streptococcus was in the causal pathway for 2.0% (9 of 454) of deaths between 7 and 90 days of age.[10] That places pediatric primary care, emergency departments and readmission pathways inside the GBS continuum, not outside it.

A reliable continuum therefore needs one shared view of maternal status, prophylaxis given, newborn evaluation and post-discharge contact points, with ownership defined at each transfer. The test is practical. When a patient screened in one clinic gives birth elsewhere, or a newborn returns to an emergency department at six weeks, can the receiving team see the earlier record without a phone call?

Figure 3

Why the pathway breaks

Cause-and-effect diagram: A person with GBS colonization or unknown status gives birth without timely, appropriate intrapartum prophylaxis, or GBS disease in the infant is not anticipated or recognized after birthUnranked qualitative cause-and-effect diagram for the outcome in the box: A person with GBS colonization or unknown status gives birth without timely, appropriate intrapartum prophylaxis, or GBS disease in the infant is not anticipated or recognized after birth Causes are assembled from the cited literature [1], [3], [4], [5], [6], [7], [8], [11], [12], [13], [14], [15]; categories are not weighted and their order carries no meaning.A person with GBS colonizationor unknown status gives birthwithout timely, appropriateintrapartum prophylaxis, orGBS disease in the infant isnot anticipated or recognizedafter birthPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Allergy clinic capacity too small to see labeled patients before delivery
  • Health professional information about GBS unclear or downplayed
  • Offer of allergy testing declined without follow-up conversation

Process

  • Screening visit missed or completed outside the 36 0/7 to 37 6/7 week window
  • Arrival in active labor leaves less than 4 hours for prophylaxis
  • Penicillin allergy labels carried into labor without evaluation

Technology

  • GBS result and allergy status not visible in the labor unit record
  • Laboratory method with lower yield than PCR after enrichment
  • No shared view of maternal prophylaxis in newborn records

Environment

  • Late-pregnancy visits harder to attend for some patients and care models
  • Births at facilities other than the one holding the prenatal record
  • Post-discharge period when late-onset disease presents outside the birth hospital

Policy

  • Narrow screening window leaves little time to recover from a missed step
  • No current public health intervention for late-onset disease
  • Maternal vaccine still in development

Measurement

  • Prophylaxis adequacy not reported by arrival timing
  • Allergy delabeling reach not stratified by race or insurance
  • Newborn antibiotic exposure not benchmarked against confirmed cases

Unranked qualitative cause-and-effect diagram for the outcome in the box: A person with GBS colonization or unknown status gives birth without timely, appropriate intrapartum prophylaxis, or GBS disease in the infant is not anticipated or recognized after birth Causes are assembled from the cited literature [1], [3], [4], [5], [6], [7], [8], [11], [12], [13], [14], [15]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleAllergy clinic capacity too small to see labeled patients before delivery; Health professional information about GBS unclear or downplayed; Offer of allergy testing declined without follow-up conversation
ProcessScreening visit missed or completed outside the 36 0/7 to 37 6/7 week window; Arrival in active labor leaves less than 4 hours for prophylaxis; Penicillin allergy labels carried into labor without evaluation
TechnologyGBS result and allergy status not visible in the labor unit record; Laboratory method with lower yield than PCR after enrichment; No shared view of maternal prophylaxis in newborn records
EnvironmentLate-pregnancy visits harder to attend for some patients and care models; Births at facilities other than the one holding the prenatal record; Post-discharge period when late-onset disease presents outside the birth hospital
PolicyNarrow screening window leaves little time to recover from a missed step; No current public health intervention for late-onset disease; Maternal vaccine still in development
MeasurementProphylaxis adequacy not reported by arrival timing; Allergy delabeling reach not stratified by race or insurance; Newborn antibiotic exposure not benchmarked against confirmed cases

Access

Making the screening visit, the specimen and allergy evaluation reachable

Universal screening assumes that every pregnant person attends a visit inside a two-week window late in pregnancy. The window was set so that results would remain accurate up to 41 0/7 weeks, which makes the timing of that single visit consequential.[3] Attendance is not uniform. In a study of 1,034 patients at two obstetric clinics in one large midwestern health system, patients in the resident-led clinic attended 1.13 fewer appointments than those in the attending-led clinic.[7] This gap occurred despite similar numbers of scheduled appointments.[7] When a visit is missed late in pregnancy, the practical result is often a patient who arrives in labor without a current result.

Self-collection can widen the ways a specimen is obtained, but it is not a simple substitute. A systematic review and meta-analysis of eleven diagnostic accuracy studies with 3269 participants found that self-collected samples had high specificity but lower sensitivity than provider-collected samples.[9] Pooled sensitivity was 82% in four trials and 91% in seven non-randomized studies.[9] No included study assessed health outcomes.[9] In a Slovenian multicenter study of 227 pregnant women, detection was 18% with healthcare worker-collected swabs and 19% with self-collected swabs.[5] PCR from enrichment broth outperformed enrichment culture, and 58.5% of women surveyed preferred healthcare worker collection.[5] The method chosen by the laboratory therefore matters as much as who collects the swab.

Access to penicillin allergy evaluation is the other gap. In a quality improvement project, 236 of 1266 prenatal patients (19%) reported a penicillin allergy; of the 150 offered testing, 101 (67%) completed it, and 94 (93%) tested negative and were de-labeled.[14] All 17 de-labeled patients who later tested positive for GBS colonization received intrapartum penicillin without adverse events.[14] In an obstetric cohort at a second academic health system, 299 of 728 patients with a penicillin allergy label were seen in a drug allergy clinic.[4] Of those seen, 270 (90.3%) had the label removed.[4]

These studies point to access as a capacity question. Visits, collection options, laboratory methods and allergy appointments each need to be available in the weeks before birth, when there is little time to recover from a missed step. For executives, the practical test is whether every patient can still complete each step in time. That includes patients who cannot attend a weekday visit, receive care at a community site or plan to give birth at a different facility. Transportation, clinic hours, language access and the location of allergy services all shape that answer, and none of them is visible in a single screening rate.

Executive guidance · System route

Map the path from first contact to verified follow-through.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Protect continuity
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Protect continuity

    Clarify how information, questions, and unresolved needs remain owned across settings, time periods, teams, and community partners relevant to the local route.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryProtectcontinuityProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Protect continuityClarify how information, questions, and unresolved needs remain owned across settings, time periods, teams, and community partners relevant to the local route.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Equity gaps in visits, allergy labels and the experience of care

Differences in prenatal care access translate directly into differences in screening opportunity. In the resident-led clinic described above, Black patients with public insurance attended fewer appointments than White patients with public insurance (7.60 versus 9.64).[7] The authors concluded that the resident care model may underserve patients who are more vulnerable to prenatal care non-adherence.[7] For GBS prevention, attendance gaps late in pregnancy are an equity measure, not only a scheduling metric.

Allergy labels are not distributed evenly either. In a diverse pregnant population, a penicillin allergy label was linked to age 35 to 51 (odds ratio 1.41 compared with 18 to 27 years) and with rhinitis, asthma or eczema (odds ratio 1.55).[6] Black race was associated with lower odds of a label (odds ratio 0.59 compared with White race).[6] The authors noted that these patterns may affect health outcomes and penicillin allergy interventions in pregnancy.[6] Delabeling programs should therefore report who they reach, not only how many labels they remove.

Trust is part of access. In a cohort of 514 Black postpartum women who gave birth in Detroit between 2023 and 2025, investigators validated a scale measuring racial microaggressions during prenatal care (internal consistency alpha 0.97).[2] They called for further development of items specific to prenatal care.[2] Tools of this kind give organizations a way to measure respectful care in the same population whose visit attendance and screening completion they track.

Global evidence shows how unevenly the burden falls. In the multicountry postmortem study, the share of infant deaths and stillbirths attributed to group B streptococcus ranged from 0.3% in Sierra Leone to 7.2% in South Africa.[10] Among GBS-attributed deaths with birth weight data, 61.9% were in infants weighing less than 2500 grams.[10] Qualitative research in the United Kingdom also called for more work on testing acceptability among women from different ethnic backgrounds and women planning home births.[12]

An equity review of the GBS pathway should look at the steps the evidence identifies: late-pregnancy visit attendance, screening completion, allergy labels and evaluation, prophylaxis adequacy and the experience of care. Each should be stratified locally and reviewed with the communities served. Allergy histories, consent for testing and explanations of a positive result all depend on language access and enough visit time. Those conditions belong in the same review, not in a separate patient experience report.

A bilingual patient navigator sits with a visibly pregnant woman and her mother on a low sofa, walking them through a simple picture card with no words, a tablet with….
Illustrative image. Prenatal appointment attendance differed by care model, race and insurance in one health system.[7]

Human infrastructure

The people who carry GBS prevention across clinics, laboratories and labor units

GBS prevention depends on roles that rarely sit in the same department. They include prenatal nurses and midwives, obstetric clinicians, laboratory staff, allergy specialists, pharmacists, labor triage nurses, neonatal teams and pediatric primary care. When any of these roles lacks time or clear responsibility, the effect appears as a missing result, an unevaluated label or an antibiotic started too late, rather than as a visible staffing failure.

Nursing-led identification can make allergy evaluation routine. In the prenatal quality improvement project, nursing staff used an eligibility algorithm to identify patients for multistep penicillin allergy testing, and 212 of the 236 patients reporting an allergy were eligible.[14] Of the 150 offered testing, 49 (33%) declined.[14] The offer itself therefore needs time, explanation and follow-up.

Specialist capacity determines reach. In the obstetric cohort with 728 labeled patients, 299 were seen in the drug allergy clinic.[4] Penicillin G was used for GBS prophylaxis in 87.5% of patients de-labeled there, compared with 24.5% of those not seen.[4] No patient experienced an IgE-mediated anaphylactic reaction to an oral drug challenge, and the authors concluded that identifying and testing patients before delivery increased use of first-line prophylaxis.[4] The constraint in that model is the number of patients the clinic can see before birth.

Care models and communication skills also matter. Patients in a resident-led prenatal clinic attended fewer appointments than those in an attending-led clinic.[7] That makes staffing design an access decision. Women interviewed in the United Kingdom reported that information from health professionals about GBS was often unclear or downplayed its importance.[12] Training and shared scripts are therefore part of the workforce plan.

Laboratory and newborn teams sit at either end of the pathway. In the Slovenian study, PCR performed on enrichment broth detected more positive specimens than enrichment culture in both collection groups.[5] Adopting a method of that kind has implications for laboratory staffing, instrument time, courier schedules and turnaround commitments to prenatal clinics. At the Canadian tertiary center, antibiotic exposure for suspected early-onset sepsis reached 238 antibiotic days per 1,000 livebirths, and 433 antibiotic days were given for each confirmed case.[1] Workforce planning for GBS should therefore count prenatal, laboratory, allergy, labor and newborn time together, and should treat role clarity at each handoff as part of capacity rather than as an afterthought.

Executive guidance · Operating dashboard

Measure whether the operating route works as intended.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilityContinuity across settingsImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Continuity across settings

Can people and teams see who owns the next step when responsibility crosses a setting or service?

Candidate local measure
Locally defined transition acknowledgment, unresolved work, repeat contacts, escalation, and experience feedback.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsContinuity across settingsOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Continuity across settingsSending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Keep work owned when it crosses a boundary.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. State who owns the next contact and how the person or family can identify the approved next step.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Ask questions that connect intent, ownership, and results.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signal Executive question Candidate owner Suggested review point
Entry-point clarity Can people and staff identify the approved first step without searching across conflicting instructions? Executive sponsor and operational lead At campaign launch and close
Ownership reliability Does a specific team accept each request and make its status visible? Operational owner and participating teams At a locally defined cadence
Continuity across settings Can people and teams see who owns the next step when responsibility crosses a setting or service? Sending and receiving owners At a locally defined cadence
Improvement closure Does the organization correct recurring friction and report what changed? Improvement owner and executive sponsor Until action is verified

Figure 5

Control points for a reliable GBS prevention pathway

Figure 5: Control points for a reliable GBS prevention pathway
Control pointRisk if missingOwnerEvidence of control
Screening visit scheduled and tracked inside the 36 0/7 to 37 6/7 week windowPatients reach labor with no current result, especially those with lower late-pregnancy attendanceAmbulatory obstetrics medical director with clinic operations leadShare of births with a result from the recommended window, stratified by clinic model, race and insurance
Specimen collection method and laboratory test matched to evidenceLower detection yield and unclear choices for patientsLaboratory medical director with obstetric quality leadDocumented collection options, test method and positivity rate reviewed at a set cadence
Penicillin allergy label evaluation before deliveryLabeled patients receive alternative agents and newborns receive more testingAllergy program lead with obstetric and pharmacy leadersShare of labeled patients evaluated before birth and share receiving first-line prophylaxis
Result and allergy status visible to the labor unit at admissionProphylaxis delayed or omitted while status is clarifiedLabor and delivery nurse manager with clinical informaticsShare of admissions with GBS status and allergy evaluation visible at triage
Time from admission to first prophylaxis doseAdequacy falls when labor is fast and ordering or administration is slowLabor and delivery medical director and pharmacyAdequacy rate reported separately for patients arriving in active labor
Newborn evaluation and antibiotic exposure benchmarkedAntibiotic exposure far exceeds confirmed disease without visibilityNeonatal medical director with antimicrobial stewardshipNewborns treated and antibiotic days per confirmed case reviewed quarterly
Early-onset, late-onset and GBS-related stillbirth case reviewPathway failures repeat without an ownerChief medical officer and board quality committeeEvery case reviewed for screening, result, allergy and prophylaxis steps with actions tracked

Control points derived from the cited evidence [1], [3], [4], [5], [7], [8], [9], [11], [14], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Communicating GBS prevention in ways that support informed choice

Public communication about GBS should help people understand why a test is offered, when it happens and what follows from the result. In interviews with 19 pregnant and postpartum women in the United Kingdom, awareness of GBS varied, information from health professionals was often unclear, and participants wanted more information.[12] Women’s motivations for testing included seeing it as routine, lowering their baby’s risk of becoming unwell, reassurance, preparation for birth and making informed choices.[12] Common concerns included the invasiveness of the procedure, risks to mother and baby and the prospect of receiving antibiotics.[12] The authors concluded that women need clear, detailed information and that their concerns should be addressed.[12]

Communication about collection options needs to be accurate. Self-collected samples showed high specificity but lower sensitivity than provider-collected samples in pooled analyses, and no included study measured health outcomes.[9] In the Slovenian study, most women surveyed preferred healthcare worker collection even though self-collected swabs detected GBS at a similar rate.[5] Messages should therefore describe the options the organization actually offers and avoid implying that one method suits everyone.

Penicillin allergy labels are a communication opportunity before labor. In the prenatal quality improvement project, nearly one in five patients receiving prenatal care reported a penicillin allergy, and most of those tested were de-labeled.[14] Organizations that offer evaluation during pregnancy can describe a specific, scheduled service rather than a general invitation to discuss allergies. Materials should be available in the languages the organization serves and should explain plainly why the question is asked before labor rather than during it.

Families also need to understand that prevention at birth does not address every risk. Surveillance authors noted that there is no current public health intervention for late-onset disease.[15] A modeling study of one annual global cohort of 140 million pregnant women assumed 80% efficacy for a maternal vaccine still under development.[13] It estimated that vaccination could avert 127,000 early-onset and 87,300 late-onset infant cases and 23,000 stillbirths, and would likely be cost-effective at reasonable prices.[13] Messages about future vaccines should be clear that they describe research, not an available service.

Trust grows when what is said matches what people experience. Investigators have validated a measure of racial microaggressions experienced during prenatal care among Black postpartum women.[2] A measure of that kind gives organizations a way to check whether the respectful, clear care described in public messages is what patients actually report.

An expectant couple walk hand in hand toward the doors, the woman visibly pregnant in a long coat, both seen from behind in the middle of the frame, unhurried and relaxed.
Illustrative image. In one cohort, adequate prophylaxis among women without membrane stripping rose from 46.9% to 85.8% when those who arrived in active labor and gave birth within 4 hours were excluded.[8]

Executive guidance · 90-day plan

Move from listening to a verified improvement in 90 days.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how Prenatal-onset GBS Disease Recognition Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Test one continuity handoff across representative settings and verify that the next owner is visible.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how Prenatal-onset GBS Disease Recognition Monthcommunications connect to real entry points, owners,transitions, and escalation.Days 1–30: Map how Prenatal-onset GBS Disease Recognition Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Test one continuity handoff across representative settings andverify that the next owner is visible.Days 31–60: Test one continuity handoff across representative settings and verify that the next owner is visible.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how Prenatal-onset GBS Disease Recognition Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testTest one continuity handoff across representative settings and verify that the next owner is visible.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Carry one accountable improvement beyond the campaign window.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Listen to the people closest to the route, assign one barrier, and verify the change.

Executive action kit · Month observance

Turn Prenatal-onset GBS Disease Recognition Month into accountable action.

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Take it with you

Filed under

Public Health and PreventionHealth Equity and AccessMonth

Leadership focus

Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the maternal, perinatal, escalation, and continuity pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review listening, respectful treatment, language access, transportation, digital access, and variation in experience using locally appropriate data and protected feedback.

Five-minute briefing

Inspect the operating sequence

Listen with patients, families, maternity teams, emergency services, ambulatory partners, and community supports. Find one a concern that is not heard, an escalation that lacks ownership, or a transition that loses context, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Protect continuity
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined transition acknowledgment, unresolved work, repeat contacts, escalation, and experience feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Public Health and Community Partners
Staff communication template

During Prenatal-onset GBS Disease Recognition Month, our organization will connect awareness with a practical review of the maternal, perinatal, escalation, and continuity pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

Prenatal-onset GBS Disease Recognition Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Antibiotic exposure for suspected early-onset sepsis in late-preterm and full-term newborns in Quebec: a 11-year single-center cohort study. Frontiers in Pediatrics. 2026;14:1922279. https://doi.org/10.3389/fped.2026.1922279
  2. 2. Measurement of Racial Microaggressions During Pregnancy and While Receiving Prenatal Care: a Validation Study of the Daily Life Experiences Scale Among Black Postpartum Women. Journal of Racial and Ethnic Health Disparities. 2025:online ahead of print, December 8, 2025. https://doi.org/10.1007/s40615-025-02777-z
  3. 3. Trends in Perinatal Group B Streptococcal Disease After Updated Screening Recommendations in the United States. O&G Open. 2025;2(4):e094. https://doi.org/10.1097/og9.0000000000000094
  4. 4. Screening for penicillin allergy in obstetric patients to optimize guideline directed therapy. Antimicrobial Stewardship & Healthcare Epidemiology. 2025;5(1):e125. https://doi.org/10.1017/ash.2025.10033
  5. 5. Comparison of self-collected and healthcare worker-collected rectovaginal swabs for group B streptococcus detection in pregnancy using PCR with a commercial collection-enrichment device. Frontiers in Microbiology. 2025;16:1541319. https://doi.org/10.3389/fmicb.2025.1541319
  6. 6. Demographic characteristics associated with a penicillin allergy label during pregnancy. Frontiers in Allergy. 2024;5:1511392. https://doi.org/10.3389/falgy.2024.1511392
  7. 7. Resident Versus Attending Prenatal Care Models: an Analysis of the Effects of Race and Insurance on Appointment Attendance. Journal of Racial and Ethnic Health Disparities. 2024;11(4):1964-1972. https://doi.org/10.1007/s40615-023-01665-8
  8. 8. Membrane stripping in group B streptococcus carriers does not impede adequate intrapartum antibiotic prophylaxis: a retrospective study. Frontiers in Medicine. 2024;11:1368998. https://doi.org/10.3389/fmed.2024.1368998
  9. 9. Self-collection of samples for group B streptococcus testing during pregnancy: a systematic review and meta-analysis. BMC Medicine. 2023;21(1):498. https://doi.org/10.1186/s12916-023-03186-x
  10. 10. Stillbirths and Neonatal Deaths Caused by Group B Streptococcus in Africa and South Asia Identified Through Child Health and Mortality Prevention Surveillance (CHAMPS). Open Forum Infectious Diseases. 2023;10(9):ofad356. https://doi.org/10.1093/ofid/ofad356
  11. 11. Antibiotic choice for Group B Streptococcus prophylaxis in mothers with reported penicillin allergy and associated newborn outcomes. BMC Pregnancy and Childbirth. 2023;23(1):400. https://doi.org/10.1186/s12884-023-05697-0
  12. 12. Women’s knowledge of and attitudes towards group B streptococcus (GBS) testing in pregnancy: a qualitative study. BMC Pregnancy and Childbirth. 2023;23(1):339. https://doi.org/10.1186/s12884-023-05651-0
  13. 13. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness. PLOS Medicine. 2023;20(3):e1004068. https://doi.org/10.1371/journal.pmed.1004068
  14. 14. Improving routine prenatal penicillin allergy testing for reported penicillin allergy. BMJ Open Quality. 2022;11(3):e001859. https://doi.org/10.1136/bmjoq-2022-001859
  15. 15. Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance. JAMA Pediatrics. 2019;173(3):224-233. https://doi.org/10.1001/jamapediatrics.2018.4826

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
U.S. early-onset and late-onset GBS incidence, missed prophylaxis among early-onset cases and antimicrobial resistance[15]2019Executive openingSurveillance in selected counties of 10 states, 2006 to 2015; predates the 2019 screening window change.
GBS in stillbirths and infant deaths in low- and middle-income countries[10]2023Executive openingPostmortem sampling in seven countries in Africa and South Asia; not directly generalizable to U.S. settings.
Early-onset disease trends after the 2019 change to a 36 0/7 to 37 6/7 week screening window[3]2025Current evidenceBefore-and-after comparison of surveillance periods with 2019 excluded; association, not proof of cause.
Adequacy of intrapartum prophylaxis and the role of arrival in active labor[8]2024Current evidenceRetrospective single-cohort study of term singleton pregnancies eligible for vaginal birth.
Antibiotic choice and newborn testing when a penicillin allergy is documented[11]2023Current evidenceSingle high-volume urban hospital, 2005 to 2018; newborn outcome differences limited to laboratory draws.
Prevalence and demographic distribution of penicillin allergy labels in pregnancy[6]2024Equity and trustElectronic record data from one large health system, 2020 to 2022; labels, not confirmed allergy.
Newborn antibiotic exposure for suspected early-onset sepsis relative to confirmed cases[1]2026Continuum of careSingle Canadian tertiary center; does not report GBS-specific results.
Prenatal appointment attendance by care model, race and insurance[7]2024AccessTwo clinics in one midwestern health system, 2020 to 2021, during the COVID-19 period.
Accuracy and acceptability of self-collected GBS specimens and PCR after enrichment[9] [5]2025, 2023AccessIncluded studies at high or unclear risk of bias; no health outcomes; single-country prospective study.
Prenatal penicillin allergy testing and delabeling and their effect on first-line prophylaxis[14] [4]2025, 2022Human infrastructureSingle-institution quality improvement project and single-institution retrospective cohort.
Measuring racial microaggressions during prenatal care[2]2025Equity and trustValidation in Black postpartum women in one city; modest model fit; not linked to GBS outcomes.
Women’s knowledge of and attitudes toward GBS testing[12]2023Public communicationQualitative interviews with 19 women in the United Kingdom, where routine testing is not standard.
Projected global impact and cost-effectiveness of maternal GBS vaccination[13]2023Public communicationModeling study with assumed 80% efficacy and prices; vaccine not yet available.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.